These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Inhibition of Candida albicans secreted aspartic protease by a novel series of peptidomimetics, also active on the HIV-1 protease. Skrbec D; Romeo D Biochem Biophys Res Commun; 2002 Oct; 297(5):1350-3. PubMed ID: 12372437 [TBL] [Abstract][Full Text] [Related]
29. Aspartic protease inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis. Braga-Silva LA; Santos AL Curr Med Chem; 2011; 18(16):2401-19. PubMed ID: 21568917 [TBL] [Abstract][Full Text] [Related]
30. Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002-2010). Calugi C; Trabocchi A; Guarna A Expert Opin Ther Pat; 2011 Mar; 21(3):381-97. PubMed ID: 21241212 [TBL] [Abstract][Full Text] [Related]
31. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine. Le VD; Mak CC; Lin YC; Elder JH; Wong CH Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177 [TBL] [Abstract][Full Text] [Related]
33. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Abad-Zapatero C; Goldman R; Muchmore SW; Hutchins C; Stewart K; Navaza J; Payne CD; Ray TL Protein Sci; 1996 Apr; 5(4):640-52. PubMed ID: 8845753 [TBL] [Abstract][Full Text] [Related]
34. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. Bektić J; Lell CP; Fuchs A; Stoiber H; Speth C; Lass-Flörl C; Borg-von Zepelin M; Dierich MP; Würzner R FEMS Immunol Med Microbiol; 2001 Jul; 31(1):65-71. PubMed ID: 11476984 [TBL] [Abstract][Full Text] [Related]
35. Structure-based specificity mapping of secreted aspartic proteases of Candida parapsilosis, Candida albicans, and Candida tropicalis using peptidomimetic inhibitors and homology modeling. Majer F; Pavlícková L; Majer P; Hradilek M; Dolejsí E; Hrusková-Heidingsfeldová O; Pichová I Biol Chem; 2006 Sep; 387(9):1247-54. PubMed ID: 16972793 [TBL] [Abstract][Full Text] [Related]
36. X-ray structures of retroviral proteases and their inhibitor-bound complexes. Ringe D Methods Enzymol; 1994; 241():157-77. PubMed ID: 7854176 [No Abstract] [Full Text] [Related]
37. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors. Migliorati CA; Birman EG; Cury AE Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Sep; 98(3):301-10. PubMed ID: 15356467 [TBL] [Abstract][Full Text] [Related]
38. Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans. Schaller M; Krnjaic N; Niewerth M; Hamm G; Hube B; Korting HC J Med Microbiol; 2003 Mar; 52(Pt 3):247-249. PubMed ID: 12621090 [TBL] [Abstract][Full Text] [Related]
39. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264 [TBL] [Abstract][Full Text] [Related]